When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 500.39% and ...
The U.S. Food and Drug Administration (FDA) has proposed a new rule to require standardized testing of talc-containing ...
1d
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
Lower interest rates boost biotech investments by increasing risk appetite, benefiting pre-commercial biotechs. Read more on how these companies may perform in 2025.
While Lilly and Novo Nordisk have each been approved to treat weight loss, it's important to understand the finer details of ...
The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...
An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback